Angiopoietin like protein 3 (Angptl3), fatty acid binding protein 4 (FABP4) and homeostasis model assessment of insulin resistance (HOMA-IR) among Indonesian obese non diabetic males

Abstract Background: Adipocyte fatty acid–binding protein (A-FABP) is traditionally thought to be a cytosolic fatty acid chaperone expressed in adipocytes. Mice with targeted disruption of the A-FABP gene exhibit a striking phenotype with strong protection from insulin resistance, hyperglycemia, and atherosclerosis. The clinical relevance of these findings remains to be confirmed. Methods: We used tandem mass spectrometry–based proteomic analysis to identify proteins secreted from adipocytes and present in human serum. We measured serum A-FABP concentrations in 229 persons (121 men and 108 women; age range, 33–72 years), including 100 lean [body mass index (BMI) <25 kg/m2] and 129 overweight/obese individuals (BMI >25 kg/m2) selected from a previous cross-sectional study. Results: A-FABP was released from adipocytes and was abundantly present in human serum. Mean (SD) circulating concentrations of A-FABP were significantly higher in overweight/obese than in lean persons [32.3 (14.8) vs 20.0 (9.8) μg/L; P <0.001]. Age- and sex-adjusted serum A-FABP concentrations correlated positively (P <0.005) with waist circumference, blood pressure, dyslipidemia, fasting insulin, and the homeostasis model assessment insulin resistance index. Moreover, we observed a significant increase in A-FABP concentrations corresponding with increases in the number of components of the metabolic syndrome (P <0.05). Conclusions: A-FABP is a circulating biomarker closely associated with obesity and components of the metabolic syndrome, and measurement of serum concentrations of A-FABP might be useful for clinical diagnosis of obesity-related metabolic and cardiovascular disorders.

Download Full-text

Association between Ala54Thr substitution of the fatty acid-binding protein 2 gene with insulin resistance and intra-abdominal fat thickness in Japanese men

Diabetologia ◽

10.1007/s001250050737 ◽

1997 ◽

Vol 40 (6) ◽

pp. 706-710 ◽

Cited By ~ 84

Author(s):

K. Yamada ◽

X. Yuan ◽

S. Ishiyama ◽

K. Koyama ◽

F. Ichikawa ◽

...

Keyword(s):

Insulin Resistance ◽

Fatty Acid ◽

Fatty Acid Binding Protein ◽

Binding Protein ◽

Abdominal Fat ◽

Japanese Men ◽

Fatty Acid Binding ◽

Acid Binding Protein ◽

Fat Thickness

Download Full-text

Serum fatty acid-binding protein 4 levels are higher in lean adolescents with insulin resistance

Atherosclerosis ◽

10.1016/j.atherosclerosis.2021.06.531 ◽

2021 ◽

Vol 331 ◽

pp. e174

Author(s):

K. P. Gutierrez Castro ◽

R. Caccavello ◽

M.E. Garay-Sevilla ◽

A. Gugliucci

Keyword(s):

Insulin Resistance ◽

Fatty Acid ◽

Fatty Acid Binding Protein ◽

Binding Protein ◽

Serum Fatty Acid ◽

Fatty Acid Binding ◽

Acid Binding Protein

Download Full-text

Associations between Fatty Acid-Binding Protein 4–A Proinflammatory Adipokine and Insulin Resistance, Gestational and Type 2 Diabetes Mellitus

Cells ◽

10.3390/cells8030227 ◽

2019 ◽

Vol 8 (3) ◽

pp. 227 ◽

Cited By ~ 7

Author(s):

Marcin Trojnar ◽

Jolanta Patro-Małysza ◽

Żaneta Kimber-Trojnar ◽

Bożena Leszczyńska-Gorzelak ◽

Jerzy Mosiewicz

Keyword(s):

Diabetes Mellitus ◽

Insulin Resistance ◽

Fatty Acid ◽

Fatty Acid Binding Protein ◽

Binding Protein ◽

Clinical Aspects ◽

Diabetic Patients ◽

Fatty Acid Binding ◽

Acid Binding Protein

There is ample scientific evidence to suggest a link between the fatty acid-binding protein 4 (FABP4) and insulin resistance, gestational (GDM), and type 2 (T2DM) diabetes mellitus. This novel proinflammatory adipokine is engaged in the regulation of lipid metabolism at the cellular level. The molecule takes part in lipid oxidation, the regulation of transcription as well as the synthesis of membranes. An involvement of FABP4 in the pathogenesis of obesity and insulin resistance seems to be mediated via FABP4-dependent peroxisome proliferator-activated receptor γ (PPARγ) inhibition. A considerable number of studies have shown that plasma concentrations of FABP4 is increased in obesity and T2DM, and that circulating FABP4 levels are correlated with certain clinical parameters, such as body mass index, insulin resistance, and dyslipidemia. Since plasma-circulating FABP4 has the potential to modulate the function of several types of cells, it appears to be of extreme interest to try to develop potential therapeutic strategies targeting the pathogenesis of metabolic diseases in this respect. In this manuscript, representing a detailed review of the literature on FABP4 and the abovementioned metabolic disorders, various mechanisms of the interaction of FABP4 with insulin signaling pathways are thoroughly discussed. Clinical aspects of insulin resistance in diabetic patients, including women diagnosed with GDM, are analyzed as well.

Download Full-text